Work

Small bowel bacterial overgrowth is found in 71% of IBS patients and associated symptoms respond well to Rifaximin in a phase IV trial

Year: 2012

Type: article

Study design: Clinical Trial

Source: IRIS

Authors: Meyrat, P., Schoepfer, A.

Language: English

Topic: Gastrointestinal motility and disorders

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7062239326

FWCI:

Cites:

Cited by:

Related to: 10